title: Risk of neurodevelopmental abnormalities in children treated with propranolol.
authors.affiliation: Pediatric Dermatology Unit, Pellegrin Children's Hospital, Place Amélie Raba-Leon, Bordeaux, 33076, France. christine.labreze@chu-bordeaux.fr.
authors.forename: C
authors.initials: C
authors.lastname: Labrèze
authors.affiliation: Pierre Fabre Dermatologie, Lavaur, France.
authors.forename: J-J
authors.initials: JJ
authors.lastname: Voisard
authors.affiliation: Pierre Fabre Dermatologie, Lavaur, France.
authors.forename: A
authors.initials: A
authors.lastname: Delarue
authors.affiliation: Departement de Pharmacologie, Université de Bordeaux, Bordeaux, France.
authors.forename: N
authors.initials: N
authors.lastname: Moore
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D000818:Animals; D002675:Child, Preschool; D005260:Female; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D065886:Neurodevelopmental Disorders / Q000139:chemically induced*; D011433:Propranolol / Q000009:adverse effects*; D017207:Rats, Sprague-Dawley
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol